Novel combination chemotherapy in the treatment of non-small cell lung cancer

Bibliography

• PARKIN DM, PISANI P, FERLAY J: Estimates of the worldwide incidence of eighteen major cancers in 1985. Int. J. Cancer (1993) 54(0594–606.
   PubMed Web of Science ®Google Scholar
• MAGRATH I, LITVAK J: Cancer in developing countries: opportunity and challenge. J. Nati Cancer Inst. (1993) 85(10:862–874.
   PubMedGoogle Scholar
• PISANI P, PARKIN DM, FERLAY J: Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int. J. Cancer (1993) 55(6):891–903.
   Google Scholar
• VALANIS BG: Epidemiology of lung cancer: a worldwide epidemic. Semin. Oncol. Nurs. (1996) 12(0251–259.
   PubMedGoogle Scholar
• STANLEY K, STJERNSWA RD J: Lung cancer - A worldwide health problem. Chest (1989) 96 (7):S1–S5.
   Google Scholar
• HAMMAR SP: Common neoplasms. In: Pulmonary Pathology- Tumours. Dail DH, Hammar SP, Colby TV (Eds.). Springer-Verlag, NY, USA (1995):1–156.
   Google Scholar
• SEKINE I, KODAMA T, YOKOSE T et al.: Rare pulmonary tumors - a review of 32 cases. Oncology (1998) 55 (5):431–434.
   PubMedGoogle Scholar
• BAKOWSKI MT, CROUCH JC: Chemotherapy ofnon-small cell lung cancer: a reappraisal and a look to the future. Cancer Treat. Reviews (1983) 10(3):159–72.
   PubMed Web of Science ®Google Scholar
• JOHNSON DH: Chemotherapy for unresectablenon-small cell lung cancer. Semin. Oncol. (1990) 17(4 Suppl. 7):20–29.
   Google Scholar
• SEKINE I, KUBOTA K, NISHIWAKI Y, SASAKI Y, TAMURAT, SAIJO N: Response rate as an endpoint for evaluating new cytotoxic agents in Phase II trials of non-small-cell lung cancer. Ann. Oncol. (1998) 9(10):1079–1084.
   PubMedGoogle Scholar
• LILENBAUM RC, GREEN MR: Novel chemotherapeuticagents in the treatment of non-small-cell lung cancer. Clin. Oncol. (1993) 11(7):1391–1402.
   Google Scholar
• BUNN PA Jr., KELLY K: New chemotherapeutic agentsprolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin. Cancer Res. (1998) 4(5):1087–1100.
   PubMedGoogle Scholar
• SOUQUET PJ, CHAUVIN F, BOISSEL JP et al.: Polychemo-therapy in advanced non small cell lung cancer: a meta-analysis. Lancet (1993) 342 (8862):19–21.
   PubMedGoogle Scholar
• GRILLI R, OXMAN AD, JULIAN JA: Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?' Clin. Oncol. (1993)11(10):1866–1872.
   Google Scholar
• MARINO P, PAMPALLONA S, PREATONI A, CANTONI A,INVERNIZZI F: Chemotherapy vs. supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest (1994) 106 (3):861–865.
   Google Scholar
• SOUQUET PJ, CHAUVIN F, BOISSEL JP, BERNARD JP:Meta-analysis of randomised trials of systemic chemotherapy versus supportive treatment in non-resectable non-small cell lung cancer. Lung Cancer (1995) 12 (Suppl. 1):S147–54.
   Google Scholar
• NON-AMALL CELL LUNG CANCER COLLABORATIVE GROUP: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br. Med. J. (1995) 311 (7010):899–909.
   PubMedGoogle Scholar
• MARINO P, PREATONI A, CANTONI A: Randomized trialsof radiotherapy alone versus combined chemotherapy and radiotherapy in stages Ma and Mb non-small cell lung cancer. A meta-analysis. Cancer (1995) 76(4):593–601.
   Google Scholar
• PRITCHARD RS, ANTHONY SP: Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis. Ann. Intern. Med. (1996) 125 (9):723–729.
   PubMedGoogle Scholar
• GO RS, ADJEI AA: Review of the comparative pharma-cology and clinical activity of cisplatin and carboplatin. j Clin. Oncol. (1999) 17(0:409–422.
   PubMedGoogle Scholar
• LOKICH J, ANDERSON N: Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann. Oncol. (1998) (1):13–21.
   Google Scholar
• BUNN PA: Clinical experiences with carboplatin(paraplatin) in lung cancer. Semin. Oncol. (1992) 19 (1 Suppl. 2):1–11.
   Google Scholar
• BONOMI PD, FINKELSTEIN DM, RUCKDESCHEL JC et al:Combination chemotherapy versus single agents followed by combination chemotherapy in stage W non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Gun. Oncol (1989) 7(10:1602–613.
   Google Scholar
• KLASTERSKY J, SCULIER JP, LACROIX H et al.: A random-ized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Gun. Oncol. (1990) 8(9):1556–1562.
   Google Scholar
• WANT MC, TAYLOR HL, WALL ME, COGGON P, MCPHAIL AT: Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. (1971) 93(9) :2325–2327.
   Google Scholar
• GELFAND VI: Microtubule dynamics: mechanism, regulation and function. Ann. Rev. Cell Biol. (1991) 7:93–116.
   PubMedGoogle Scholar
• DESAI A, MITCHISON TL: Mier o tubule polymerization dynamics. Ann. Rev. Cell Biol. (1997) 13:83–117
   Google Scholar
• NISHIO K, SAIJO N: Cytoskeletons and antimitotic agents developed in Japan. Anticancer Drug Design (1999) 14 (1) :133–141.
   PubMedGoogle Scholar
• ROWINSKY RK, CAZENAVE LA, DONEHOWER RC: Taxol:a novel investigational antimicrotubule agent. J Nail Cancer Inst. (1990) 82(15):1247–1259.
   PubMed Web of Science ®Google Scholar
• MONZO M, ROSELL R, SANCHEZ JJ et al.: Paclitaxelresistance in non-small cell lung cancer associated with beta-tunulin gene mutations. j Clin. Oncol. (1999) 17 (6) :1786–1793.
   PubMed Web of Science ®Google Scholar
• BELOTTI, D, VERGANI V, DRUDIS T et al.: Themicrotubule-affecting drug p aclitaxel has antiangioge-neic activity. Clin. Cancer Res. (1996) 2(11):1843–1849.
   PubMed Web of Science ®Google Scholar
• THATCHER N, RANSON M, ANDERSON H eta].: Phase III study of paclitaxel (Taxol*) (1) versus best supportive care (BSC) in inoperable non-small cell lung cancer (NSCLC). Ann. Oncol. (1998) 9 (Suppl. 4):1.
   Google Scholar
• CHOU TC, MOTZER RJ, TONG Y, BOSL GJ: Computerized quantitation of synergism and antagonism of taxol, top otecan and cisplatin against human teratocarci-noma cell growth: a rational approach to clinical protocol design. J. Natl. Cancer Inst. (1 9 9 4) 8 6 (20):1517–1524.
   Google Scholar
• JEKUNEN AP, CHRISTEN RD, SHALINSKY DR, HOWELL SB:Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br. J. Cancer (1994) 69(2):299–306.
   PubMed Web of Science ®Google Scholar
• KANO Y, AKUTSU M, TSUNODA S, SUZUKI K, YAZAWA Y:In vitro schedule-dependent interaction between paclitaxel and cisplatin in human carcinoma cell lines. Cancer Chemother. Pharmacol. (1996) 37(6)525–530.
   Google Scholar
• PARKER RJ, DABHOLKAR MD, LEE KB, BOSTICK-BRUTON F, REED E: Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells. Mon ogr. Nati Cancer Inst. (1993) 15 (1):83–88.
   Google Scholar
• ROWINSKY EK, CITARDI MJ, NOE DA, DONEHOWER RC: Sequence-dependent cytotoxic effects due to combina-tions of cisplatin and the antimicrotubule agents taxol and vincristine. J. Cancer Res. Clin. Oncol. (1993) 119 (12):727–733.
   PubMedGoogle Scholar
• UNTCH M, SEVIN BU, PERRAS JP et al.: Evaluation of paclitaxel (taxol), cisplatin, and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP cell viability assay. Gyn. Oncol. (1994) 53 (1):44–49.
   PubMedGoogle Scholar
• VANHOEFER U, HARSTRICK A, WILKE H et al.: Schedule-dependent antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell lines in vitro. Eur. J. Cancer (1995) 31A(1):92–97.
   PubMedGoogle Scholar
• LEVASSEUR LM, GRECO WR, RUSTUM YM, SLOCUM HK:Combined action of paclitaxel and cisplatin against wildtype and resistant human ovarian carcinoma cells. Cancer Chem other. Pharmacol (1997) 4 0 (6) :495–505.
   Google Scholar
• ZAFFARONI N, SILVESTRINI R, ORLANDI L, BEARZATTO A, GORNATI D, VILLA R: Induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and -resistant human ovarian cells. Br. J. Cancer (1998) 77 (9) :1378–1385.
   PubMedGoogle Scholar
• ROSE WC: Taxol-based combination chemotherapy and other in vivo preclinical antitumor studies. Monogr. Natl. Cancer Inst. (1993) 15 (0 :47–53.
   Google Scholar
• MILROSS CG, PETERS LJ, HUNTER NR, MASON KA, MILAS L: Sequence-dependent antitumor activity of p aclitax el (taxol) and cisplatin in vivo. Int. J. Cancer (1995) 62(5)599–604.
   Google Scholar
• FUJIMOTO S, CHIKAZAWA H: Schedule-dependent and -independent antitumor activity of paclitaxel-based combination chemotherapy against M-109 murine lung carcinoma in vivo. Jpn. J. Cancer Res. (1998) 89 (12):1343–1351.
   PubMedGoogle Scholar
• ROWINSKY EK, GILBERT MR, MCGUIRE WP et al.: Sequences of taxol and cisplatin: Phase land pharma-cologic study. J Clin. Oncol. (1991) 9(9):1692–1703.
   PubMed Web of Science ®Google Scholar
• HOJO F, KAKINUMA R, OHE Y et al.: Phase land pharma-cokin etic studies of paclitaxel with cisplatin in patients with non-small-cell lung cancer. Proc. Am. Soc. Clin. Oncol. (1998) 17:488a.
   Google Scholar
• KLASTERSKY J, SCULIER JP: Dose-finding study of paclitaxel (Taxol) plus cisplatin in patients with non-small cell lung cancer. European Lung Cancer WorkingParty. Lung Cancer (1995)12 (Suppl. 2):S117–25.
   Google Scholar
• BELLI L, LECHEVALIER T, GOTTFRIED M et al.: Phase VII study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results. Semin. Oncol (1996) 22(6 Suppl. 15):29–33.
   Google Scholar
• GEORGIADIS MS, SCHULER BS, BROUN JE et al.: Paclitax el by 96-hour continuous infusion in combina-tion with cisplatin: a Phase I trial in patients with Exp. Opin. Pharmacother. (2000) 1(6) advanced lung cancer. J. Clin. Oncol. (1997)15 (2)735–743.
   Google Scholar
• POSTMUS PE, GIACCONE G, DEBRUYNE C, SAHMOUD T,SPLINTER TA, VANZANDWIJK N: Results of the Phase II EORTC study comparing paclitaxel/cisplatin with teniposide/cisplatin in patients with non-small cell lung cancer. EORTC Lung Cancer Cooperative Group. Semin. Oncol (1996) 23(5 Suppl. 12):10–13.
   Google Scholar
• VON PAWEL J, WAGNER H, NIEDERLE N et al: Phase IIstudy of paclitaxel and cisplatin in patients with non-small cell lung cancer. Semin. Oncol. (1996) 23(6 Suppl. 16):47–50.
   Google Scholar
• SORENSEN JB, WEDERVANG K, DOMBERNOWSKY P: Preliminary results of a Phase II study of paclitax el and cisplatin in patients with non-small cell lung cancer. Semin. Oncol. (1997) 2 4 (4 Suppl. 12):512-18-512-20.
   Google Scholar
• HSU JW, HSU JY, CHIANG CD: Preliminary result ofPhase II study of paclitaxel and cisplatin chemotherapy for advanced non-small-cell lung cancer in Chinese patients. Am. J Clin. Oncol. (1998) 21 (5):487–490.
   PubMed Web of Science ®Google Scholar
• GATZEMEIER U, VON PAWEL J, GOTTFRIED M et al:Phase III study of high-dose cisplatin (HD-cis) versusa combination of paclitaxel (TAX) and cisplatin (cis) in patients with advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. (1998) 17:454a.
   Google Scholar
• GIACCONE G, SPLINTER TA, DEBRUYNE C et al.:Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organiza-tion for Research and Treatment of Cancer Lung Cancer Cooperative Group. J. Clin. Oncol. (1998) 16 (6):2133–2141.
   Google Scholar
• BONOMI P, KIM K, FAIRCLOUGH D et al.: Comparison ofsurvival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group Trial. J. Clin. Oncol. (2000) 18 (3):623–631.
   PubMed Web of Science ®Google Scholar
• HUIZING MT, GIACCONE G, VAN WARMERDAM LJC et al.:Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small cell lung cancer. J Clin. Oncol. (1997) 15 (1):317–329.
   Google Scholar
• OBSAJUCK, JOHNSON SW, ROGATKO A et al.: Evaluationof carboplatin pharmacokinetics in the absence and presence of paclitaxel. Clin. Cancer Res. (1996) 2 (3):549–552.
   PubMedGoogle Scholar
• KELLY K, PAN Z, MURPHY J, HUFFMAN DH, BUNN PA, Jr.:A Phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer. Clin. Cancer Res. (1997) 3(7):1117–1123.
   Google Scholar
• BELANI CP, KEARNS CM, ZUHOWSKI EG et al: Phase Itrial, including pharmacokinetic and pharmacody-namic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. J Clin. Oncol (1999) 17(2):676–684.
   PubMedGoogle Scholar
• ROWINSKY EK, FLOOD WA, SARTORIUS SE, BOWLING KM, ETTINGER DS: Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer. Invest. New Drugs (1997) 15(2):129–138.
   PubMedGoogle Scholar
• DUNPHY FR, BOYD JH, KIM HJ et al.: A Phase I report ofpaclitaxel dose escalation combined with a fixed dose of carboplatin in the treatment of head and neck carcinoma. Cancer (1997) 79(102016–2023.
   Google Scholar
• SIDDIQUI N, BODDY AV, THOMAS HD et al: A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer. Br. J. Cancer (1997) 75 (2):287–294.
   PubMedGoogle Scholar
• NATALE RB: Preliminary results of a Phase VII clinical trial of paclitaxel and carboplatin in non-small cell lung cancer. Semin. Oncol. (1996) 23(5 Suppl. 12):2–6.
   Google Scholar
• GIACCONE G, HUIZING M, POSTMUS PE et al.:Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer. Semin. Oncol. (1995) 2 2 (4 Suppl. 9):78–82.
   Google Scholar
• BOOKMAN MA, MCGUIRE WP III, KILPATRICK D et al. Carboplatin and paclitaxel in ovarian carcinoma: Phase I study of the Gynecologic Oncology Group. J Clin. Oncol. (1996) 1 4 (6):1895–1902.
   Google Scholar
• DE BOIS A, Le CK HJ, BAUKNECHT T et al: Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer. Ann. Oncol. (1997) 8:355–361.
   PubMedGoogle Scholar
• BELANI CP, NATALE RB, LEE JS et al.: Randomized Phase III trial comparing cisplatin/etoposide versus carboplatin /p aclitax el in advanced and metastatic non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. (1998) 17:455a.
   Google Scholar
• DU BOIS A, RICHTER B, WARM M et al.:Cisplatin /p aclitax el vs. carboplatin /p aclitax el as 1st-line treatment in ovarian cancer. Proc. Am. Soc. Clin. Oncol. (1999) 18:361a
   Google Scholar
• GATZEMEIER U, ROSELL R, BELTICHER D et al.: Random- izedPan-Europeantrialcomparingpaclitaxel/carboplatin versus paclitaxel/cisplatin in advanced non-small cell lung cancer. Eur. J Cancer (1999) 35 (Suppl. 4):5246.
   Google Scholar
• KOSMIDIS PA, MYLONAKIS N, SKARLOS D et al.: Amulticenter randomized trial of paclitaxel (175 mg/m2) plus carboplatin (6AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6AUC) in advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. (1999) 18:463a
   Google Scholar
• BISSERY MC, NOHYNEK G, SANDERINK GJ, LAVELLE F:Docetax el (Taxotere®): a review of preclinical and clinical experience. Part I: preclinical experience. Anticancer Drugs (1995) 6 (1):339–368.
   PubMedGoogle Scholar
• CORTES JE, PAZDUR R: Docetaxel. J. Clin. Oncol (1995) 13(102643–2655.
   Google Scholar
• DIAZ JF, ANDREU JM: Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: Exp. Opin. Pharmacother. (2000) 1(6) reversibility, ligand stoichiometry and competition. Biochemistry (1993) 32(11) :2747–2755.
   Google Scholar
• RINGEL I, HORWITZ SB: Studies with RP 56976(Taxotere): a semisynthetic analogue of Tax ol. j Nail Cancer Inst. (1991) 83 (4) :288–291.
   PubMedGoogle Scholar
• GUERITTE-VOEGELEIN F, GUENARD D, LAVELLE F, LE GOFF ME, MANGATAL L, POTTER P: Relationships between the structure of taxol analogues and their antimitotic activity. J Med. Chem. (1991) 34(3):992–998.
   PubMed Web of Science ®Google Scholar
• FROMES Y, GOUNON P, VEITIA R, BISSERY MC, FELLOUSA: Influence of microtubule-associated proteins on the differential effects of paclitaxel and docetaxel. J. Protein Chem. (1996) 15 (4) :377–388.
   PubMedGoogle Scholar
• ANDREU JM, DIAZ JF, GIL R et al.: Solution structure ofTaxotere-induced microtubules to 3-nm resolution. J Biol. Chem. (1994) 269(50):31785–31792.
   PubMedGoogle Scholar
• RIOU JF, PETIGENET 0, COMBEAU C, LAVELLE F: Cellularuptake and efflux of do cetax el (Tax otere) and paclitaxel (Tax ol) in P388 cell line. Proc. Ann. Meet. Am. Assoc. Cancer Res. (1994) 35:A2292.
   Google Scholar
• HALDAR S, BASU A, CROCE CM: Bc12 is the guardian of microtubule integrity. CancerRes. (1997) 57(2) :229–233.
   Google Scholar
• HENNEQUIN C, GIOCANTI N, FAVAUDON V: S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells. Br. J. Cancer (1995) 71(6):1194–1198.
   PubMedGoogle Scholar
• KELLAND LR, ABEL G: Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother. Pharmacol. (1992) 3 0 (6):444–450.
   Google Scholar
• VOGEL M, HILSENBECK SG, DEPENBROCK H et al: Preclinical activity of Taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumor cells: comparison with Tax ol and conventional antineoplastic agents. Eur. J. Cancer (1993) 29A(14):2009–2014.
   PubMed Web of Science ®Google Scholar
• RIOU JF, NAUDIN A, LAVELLE F: Effects of Taxotere on murine and human tumor cell lines. Biochem. Biophys. Res. Commun. (1992) 187(0:164–170.
   PubMedGoogle Scholar
• UNTCH M, UNTCH A, SEVIN BU et al: Comparison of paclitaxel and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with the ATP-cell viability assay. Anticancer Drugs (1994) 5 (1) 24–30.
   PubMed Web of Science ®Google Scholar
• HANAUSKE AR, DEGEN D, HILSENBECK SG, BISSERY MC,VON HOFF DD: Effects of Tax otere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs (1992) 3 (2) :121–124.
   PubMedGoogle Scholar
• BISSERY MC, GUENAUD D, GUERITTE-VOEGELEIN F, LAVELLE F: Experimental antitumor activity of tax o ter e (RP 56976, NSC 628503), a taxol analogue. Cancer Res. (1991) 51 (18):4845–4852.
   PubMed Web of Science ®Google Scholar
• NICOLETTI MI, LUCCHINI V, D'ICALCI M, GIAVAZZI R:Comparison of paclitaxel and docetaxel activity on human ovarian carcinoma xenografts. Eur. J Cancer (1994) 30A(5) :691–696.
   PubMedGoogle Scholar
• FOSSELLA FV, LEE JS, SHIN DM et al: Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J. Clin. Oncol. (1995) 13(3):645–651.
   PubMedGoogle Scholar
• ALEXOPOULOS K, KOUROUSSIS C, ANDEROULAKIS N et al: Docetaxel and granulocyte colony-stimulating factor inpatients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial. Cancer Chemother. Pharmacol. (1999) 43 (3):257–262.
   PubMedGoogle Scholar
• NAKAMURA Y, KUNITOH H, AONO H et al: A Phase II study of low-dose docetaxel (DCT) 60 mg/m2 in platinum-pretreated advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol (1999) 18:518a.
   Google Scholar
• GANDARA DR, VOKES E, GREEN M et al: Activity of docetaxel in platinum-treated non-small cell lung cancer: results of a Phase II multicenter trial. J Clin. Oncol (2000) 18(0:131–135.
   PubMedGoogle Scholar
• SHEPHERD FA, DANCEY J, RAMLAU R et al.: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin. Oncol. (2000) 18(10) :2095–2103.
   PubMed Web of Science ®Google Scholar
• FOSSELLA FV, DEVORE R, KERR R et al: Randomized Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J. an. Oncol. (2000) 18:2354–2362.
   PubMed Web of Science ®Google Scholar
• AOE K, KIURA K, UEOKA H etal: Effect of docetaxel with cisplatin or vinorelbine on lung cancer cell lines. Anticancer Res. (1999) 1 9 (1A):291–299.
   Google Scholar
• ENGBLOM P, RANTANEN V, KULMALA J, HELENIUS H, GRENMAN S: Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines. Br. J Cancer (1999) 79(2):286–292.
   PubMedGoogle Scholar
• BISSERY M-C, VRIGNAUD P, LAVELLE F: Preclinical profile of docetaxel (Taxotere): efficacy as a single agent and in combination. Semin. Oncol. (1995) 22(6 Suppl. 13) :3–16.
   Google Scholar
• BISSERY M-C, NOHYNEK G, SANDERRINK G-J, LAVELLE F: Docetax el (Taxotere®): a review of preclinical and clinical experience. Part I: preclinical experience. Anticancer Res. (1995) 6(2) :339–368.
   PubMedGoogle Scholar
• CROWN J, FUMOLEAU P, KERBRAT Petal.: Phase I trial of docetaxel (D) with cisplatin (P) as first-line chemotherapy of metastatic breast cancer (MBC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1997) 16:821a.
   Google Scholar
• WATANABE K, HAYASHI I, HIRAKI S et al.: Phase 'Al dose escalation study of docetaxel (TXT) and cisplatin (CDDP) for stage IV non-small cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1997) 16:899a.
   Google Scholar
• PRONK LC, SCHELLENS JH, PLANTING AS et al.: Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors./ Clin. Oncol (1997) 15(3):1071–1079.
   Google Scholar
• MILLWARD MJ, ZALCBERG J, BISHOP JF et al.: Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer. J Oncol. (1997) 15(2):750–758.
   Google Scholar
• COLE JT, GRALLA RJ, MARQUES CB, RITTENBERG CN: Phase I-II study of cisplatin + docetaxel (Tax otere) in non-small cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1995) 14:1087a.
   Google Scholar
• LE CHEVALIER T, MONNIER A, DOUILLARD JY et al: Docetax el (Tax otere) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer. Eur. J Cancer (1998) 34 (13):2032–2036.
   PubMedGoogle Scholar
• GEORGOULIAS Y, ANDROULAKIS N, DIMOPOULOS AM et al.: First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: a multicenter Phase II study. Ann. Oncol. (1998) 9 (3):331–334.
   PubMedGoogle Scholar
• ZALCBERG J, MILLWARD M, BISHOP J et af: Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer. J Clin. Oncol (1998) 16(5):1948–1953.
   PubMedGoogle Scholar
• BELANI CP, BONOMI P, DOBBS T et al.: Multicenter Phase II trial of docetaxel and cisplatin combination in patients with non-small cell lung cancer. Proc. Ann. Meet. Am. Soc. Clin. Oncol (1997) 16:1660a.
   Google Scholar
• WATANABE K, HAYASHI I, SEGAWA Y, et al.: Phase I/II study of docetaxel (TXT) and cisplatin (CDDP) in patients with previously untreated metastatic non-small cell lung cancer (NSCLC). Ann. Oncol. (1998) 9 (Suppl. 4):91.
   Google Scholar
• GEORGOULIAS V, PAPADAKIS E, ALEXOPOULOS A et al.: Docetaxel plus cisplatin versus docetaxel plus gemcitabine chemotherapy in advanced non-small cell lung cancer: a preliminary analysis of a multicenter randomized Phase II trial. Proc. Am. Soc. Clin. Oncol. (1999) 18:461a
   Google Scholar
• SCHILLER JH, HARRINGTON D, SANDLER A et al: A randomized Phase III trial of four chemotherapy regimens in advanced non-small-cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (2000) 19:1a.
   Google Scholar
• TAKEDA K, YAMAMOTO N, NEGORO S et al.: Random-ized Phase II study of docetaxel (DOC) plus cisplatin (CDDP) versus DOC plus irinotecan in advanced non-small-cell lung cancer (NSCLC): a West Japan Thoracic Oncology Group (WJTOG) study. Proc. Ann. Meet. Am. Soc. Clin. Oncol (2000) 1 9:497a.
   Google Scholar
• BELANI CP, HADEED V, RAMANATHAN R et al: Do cetax el and carboplatin: a phase I and pharmacokinetic trial for advanced non-hematologic malignancies. Proc. Ann. Meet. Am. Soc. Clin. Oncol (1997) 16:771a.
   Google Scholar
• LANGER C, MCALEER C, MILLENSON M et al: Phase I evaluation of docetaxel (D) and carboplatin (C) in advanced malignancies: stratification of patient cohorts based on prior treatment (TX) status yields useful results. Proc. Annu. Meet. Am. Soc. Clin. Oncol. (1998) 17:204a.
   Google Scholar
• CAPOSSOLI MJ, BELANI CP, EINZIG A et al: Multi-institutional Phase II trial of docetax el and carboplatin combination in patients (PTS) with stage IIIB and W non-small cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol (1998) 17:479a.
   Google Scholar
• POTTER P: The synthesis of Navelbine® prototype of a new series of vinblastine derivatives. Semin. Oncol (1989) 16(2 Suppl. 4):2–4.
   Google Scholar
• BUDMAN DR. Vinorelbine (Navelbine): a third-generation vinca alkaloid. Cancer Invest. (1997) 15 (5):475–490.
   PubMedGoogle Scholar
• BINET S, FELLOUS A, LATASTE H, KRIKORIAN A, COUZINIER JP, MEININGER V: In situ analysis of the action of Navelbine® on various types of microtubules using immunofluorescence. Semin. Oncol. (1989) 16(2 Suppl. 4):5–8.
   Google Scholar
• FELLOUS A, OHAYON R, VACASSIN T et al.: Biochemical effects of Navelbine® on tubulin and associated proteins. Semin. Oncol. (1989) 16(2 Suppl. 4):9–14.
   Google Scholar
• THE ELDERLY LUNG CANCER VINORELBINE ITALIAN STUDY GROUP: Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J. Nati Cancer Inst. (1999) 91 (1):66–72.
   PubMedGoogle Scholar
• FURUSE K, FUKUOKA M, KUBA M et al: Randomized study of vinorelbine (VRB) versus vin de sin e (VDS) in previously untreated stage IIIB or IV non-small-cell lung cancer (NSCLC). The Japan Vinorelbine Lung Cancer Cooperative Study Group. Ann. Oncol. (1996) 7 (8):815–820.
   Google Scholar
• CRAWFORD J, O'ROURKE M, SCHILLER JH et al.: Random-ized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer. J Clin. Oncol. (1996) 1 4 (10):2774–2784.
   Google Scholar
• ELLIOTT JA, AHMEDZAI S, HOLE D et al: Vindesine and cisplatin combination chemotherapy compared with vindesine as a single agent in the management of non-small cell lung cancer: a randomized study. Eur. Cancer Clin. Oncol. (1984) 2 0 (8) : 1025–1032 .
   Google Scholar
• KRIS MG, GRALLA RJ, KALMAN LA etal.: Randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patients with non-small cell lung cancer, with an analysis of methods of response assessment. Cancer Treat. Rep. (1985) 6 9 (4) :387–395.
   Google Scholar
• DHINGRA JM, VALDIVIESO M, CARR DT et al: Random-ized trial of three combinations of cisplatin with vindesine and/or VP-16-213 in the treatment of advanced non-small-cell lung cancer. J Clin. Oncol (1985) 3 (2) :176–183.
   PubMed Web of Science ®Google Scholar
• PACCAGNELLA A, BRANDES A, PAPPAGALLO GL et al.: Cisplatin plus vindesine versus cisplatin plus VP16 versus doxorubicin plus cytoxan in non-small-cell carcinoma of the lung. A randomized study. Tumouri (1986) 72(4):417–425.
   PubMedGoogle Scholar
• EINHORN LH, LOEHRER PJ, WILLIAMS SD et al: Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin Exp. Opin. Pharmacother. (2000) 1(6) plus mitomycin C in advanced non-small-cell lung cancer. J Gun. Oncol. (1986) 4(7):1037–1043.
   Google Scholar
• RUCKDESCHEL JC, FINKELSTEIN DM, ETTINGER DS et al.: Arandomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Gun. Oncol. (1986) 4(0:14–22.
   Google Scholar
• RAPP E, PATER JL, WILAN A et al.: Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer - report of a Canadian multicenter randomized trial. J Gun. Oncol. (1988) 6 (4):633–641.
   Google Scholar
• WOODS RL, WILLWAMS CJ, LEVI J et al.: A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br. J Cancer (1990) 61 (4):608–611.
   PubMedGoogle Scholar
• KAWAHARA M, FURUSE K, KODAMA N eta].: A random-ized study of cisplatin versus cisplatin plus vindesine for non-small cell lung carcinoma. Cancer (1991) 68 (4):714–719.
   Google Scholar
• FUKUOKA M, MASUDA N, FURUSE K eta].: Arandomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin. J. an. Oncol. (1991) 9(4):606–613.
   Google Scholar
• CROS S, WRIGHT M, MORIMOTO M, LATASTE H, COUZINIER JP, KRIKORIAN A: Experimental antitumor activity of navelbine. Semin. Oncol. (1989) 16(2 Suppl. 4): 15–20.
   Google Scholar
• GOMI K, OHNO H, NOMURA K, OKABE M, KOBAYASHI K, NIITANI H: Kinetic analysis of combination effect of navelbine (KW-2307) with cisplatin against human lung adenocarcinoma PC-12 cells in culture. Jap. Cancer Res. (1992) 83 (5):532–539.
   Google Scholar
• ASHIZAWA T, ASADA M, KOBAYASHI E, OKABE M, GOMI K, HIRATA T: Combination effect of navelbine (vinorel-bine ditartrate) with cisplatin against murine P388 leukemia and human lung carcinoma xenografts in mice. Anticancer Drugs (1993) 4(5):577–583.
   PubMedGoogle Scholar
• ROUSSAKIS C, POUCHUS YF, GRATAS C et al: In vivo study of vinorelbine associations with cisplatin, 5-fluorouracil or actinomycin D relative to a non-small-cell lung carcinoma (NSCLCN6-L1 6). Anticancer Drug Des. (1993) 8 (2):165–171.
   PubMedGoogle Scholar
• BERTHAUD P, LE CHEVALIER T, RUFFIE P et al.: Phase I-II study of vinorelbine (Navelbine) plus cisplatin in advanced non-small cell lung cancer. Eur. J. Cancer (1992) 28A(11) :1863–1865.
   PubMedGoogle Scholar
• BRETTI S, BERRUTI A, GORZEGNO G et al: Multicenter Phase II trial of intermediate dose cisplatin and vinorelbine in inoperable non-small cell lung cancer patients. Lung Cancer (1996) 14(2-3):353–360.
   PubMedGoogle Scholar
• ADAM Z, COUPKOVA H, KOLEK V et al.:Vinorelbine and cisplatin in the treatment of advanced non-small cell lung cancer: results of a multicenter Czech study. Acta Med. Austria. (1995) 22(5):120–124.
   PubMedGoogle Scholar
• GEBBIA V, CARUSO M, VALENZA R et al: Vinorelbine plus cisplatinum for the treatment of stage IIIB and W non small cell lung carcinoma. Anticancer Res. (1994) 14 (3B):1247–1249.
   Google Scholar
• BROOKS BJ, GRALLA RJ, MCGAW HJ, OTTEN MC, LANG AC, RITTENBERG CN: Cisplatin + vinorelbine (Navelbine) combination chemotherapy for advanced non-small cell lung cancer: testing the efficacy of a regimen designed to reduce toxicity and increase dose-intensity. Proc. Ann. Meet. Am. Soc. Clin. Oncol (1994) 13:1162a.
   Google Scholar
• DEPIERRE A, CHASTANG C, QUOIX E et al: Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann. Oncol. (1994) 5(1):37–42.
   PubMedGoogle Scholar
• LE CHEVALIER T, BRISGAND D, DOUILLARD JY et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin. Oncol. (1994) 1 2 (2):360–367.
   Google Scholar
• WOZNIAK AJ, CROWLEY JJ, BALCERZAK SP et al.: Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J. Clin. Oncol. (1998) 1 6 (7):2459–2465.
   Google Scholar
• MARTONI A, GUARALDI M, PIANA E et al: Multicenter randomized clinical trial on high-dose epirubicin plus cis-platinum versus vinorelbine plus cis-platinum in advanced non small cell lung cancer. Lung Cancer (1998) 22 (1):31–38.
   PubMedGoogle Scholar
• GEBBIA V, GALATTA D, RICCARDI F et al: Mitomycin plus vindesine and cisplatin (MVP) versus vinorelbine and cisplatin (PV) in stage III-W non-small cell lung cancer: a randomized Phase III trial of the Southern Italy Oncology Group Study (G.O.I.M.). Proc. Ann. Meet. Am. Soc. Clin. Oncol (1998) 17:465a
   Google Scholar
• COLLEONI M, BONI L, VICARIO G et al: A dose-escalating study of carboplatin combined with vinorelbine in non-small-cell lung cancer. Oncology (1996) 53 (5):364–368.
   PubMedGoogle Scholar
• JACOULET P, BRETON JL, WESTEEL V, MERCIER M, GARNIER G, DEPIERRE A: Phase I study of vinorelbine and carboplatin in advanced non-small cell lung cancer. Lung Cancer (1995) 1 2 (3):247–257.
   Google Scholar
• CRAWFOLD J, O'ROURKE MA, HERNDON J, JOHNEKER J, BURMAN S: Sequential trials of vinorelbine (navelbine, NVB) with carboplatin in patients with advanced non small cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1995) 14:1162a.
   Google Scholar
• SANTOMAGGIO C, TUCCI E, RINALDINI M et al.: Carboplatin and vinorelbine in the treatment of advanced non-small-cell lung cancer: a multicenter Phase II study. Am. J. Clin. Oncol. (1998) 21(0:67–71.
   PubMedGoogle Scholar
• PRONZATO P, GHIO E, LOSARDO PL, LANDUCCI M, VAIRA F, VIGANI A: Carboplatin and vinorelbine in advanced non-small-cell lung cancer. Cancer Chemothera. Pharmacol (1996) 37 (6):610–612. Exp. Opin. Pharmacother. (2000) 1(6)
   Google Scholar
• GARST J, CRAWFORD J, O'ROURKE 0 et al.: Vinorelbine (NVB) and carboplatin (C) for the treatment of patients with advanced non-small cell lung cancer (NSCLC): a Phase II response, toxicity and survival study. Proc. Ann. Meet. Am. Soc. Clin. Oncol (1996) 15:1233a.
   Google Scholar
• MASOTTIA, BORZELLINO G, ZANNINI G, LATERZA E, RICCI F, MORANDINI G: Efficacy and toxicity of vinorelbine-carboplatin combination in the treatment of advanced adenocarcinoma or large-cell carcinoma of the lung. TumourL (1995) 81 (2) :112–116.
   PubMedGoogle Scholar
• BALDINI E, TIBALDI C, ARDIZZONI A et al: Cisplatin-vindesine-mitomycin (MVP) vs. cisplatin-ifosfamide-vinorelbine (PIN vs. car b o p latin -vin o r elbin e (Ca in patients with advanced non-small-cell lung cancer (NSCLC): a FONICAP randomized Phase II study. Italian lung Cancer Task Force (FONICAP). Br. J. Cancer (1998) 77 (12):2367–2370.
   Google Scholar
• PERIGAUD C, GOSSELIN G, IMBACH J: Nucleoside analogues as chemotherapeutic agents: a review. Nucleosides Nucleotides (1992) 11 (2-4):903–945.
   Web of Science ®Google Scholar
• HERTEL WL, KROIN JS, MISNER JW, TUSIN JM: Synthesis of 2-deoxy-2, 2-difluoro-D-ribose and 2-deoxy-2, 2-D-ribofuranosyl nucleosides. j Org. Chem. (1988) 53(102406–2409.
   Google Scholar
• BOUFFARD DY, MOMPARLER LF, MOMPARLER RL: Comparison of antineoplastic activity of 2',2'-difluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cells. Anticancer Drugs (1991) 2(1):49–55.
   PubMedGoogle Scholar
• HERTEL LW, BODER GB, KROIN JS et al.: Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). Cancer Res. (1990) 5 0 (104417–4422.
   Google Scholar
• GUCHELAAR HJ, RICHEL DK, VAN KNAPEN A: Clinical, toxicological and pharmacological aspects of gemcita-bine. Cancer Treat. Rev. (1996) 22(1):15–31.
   PubMedGoogle Scholar
• PLUNKETT W, HUANG P, XU YZ, HEINEMANN V, GRUNEWALD R, GANDHI V: Gemcitabine: metabolism, mechanisms of action and self-potentiation. Semin. Oncol. (1995) 22(4 Suppl. 10:3–10.
   Google Scholar
• ANDERSON N, COTTIER B, NICOLSON M et al: Phase III study of gemcitabine (Gemzar*) versus best suppor-tive care (BSC) in advanced non-small cell lung cancer (NSCLC). Lung Cancer (1997) 1 8 (Suppl. 0:9.
   Google Scholar
• MANEGOLD C, BERGMAN B, CHAMAISSANI A et al: Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised Phase II study in locally advanced or metastatic non-small-cell lung cancer. Ann. Oncol. (1997) 8(6):525–529.
   PubMedGoogle Scholar
• TEN BOKKEL HUININK WW, BERGMAN B, CHEMAISSANI A et al: Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer. Lung Cancer (1999) 26 (2):85–94.
   PubMedGoogle Scholar
• PERNG RP, CHEN YM, MING-LIU J et al: Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a Phase II randomized study. J Clin. Oncol (1997) 15 (5):2097–2102.
   PubMedGoogle Scholar
• CRINO L, MOSCONI AM, SCAGLIOTTI G et al: Gemcita-bine as second-line treatment for advanced non-small cell lung cancer: a Phase II trial. J Clin. Oncol. (1999) 17 (7):2081–2085.
   PubMed Web of Science ®Google Scholar
• ROSVOLD E, LANGER CJ, SCHILDER R et al.: Salvage therapy with gemcitabine in advanced non-small cell lung cancer (NSCLC) progressing after prior carboplatin-paclitaxel (C-P). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1998) 17:467a.
   Google Scholar
• GARFIELD DH, DAKHIL SR, WHITTAKER TL et al: Phase II randomized multicenter trial of two dose schedules of gemcitabine as second-line therapy in patients with advanced non-small cell lung cancer (ANSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1998) 17:484a.
   Google Scholar
• ROCCI A, PERRONE F, BARLETTA E et al: Activity of gemcitabine (GEM) in cisplatin-pretreated patients with advanced non-small cell lung cancer (NSCLC): a Phase 2 trial. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1999) 18:484a.
   Google Scholar
• VAN MOORSEL CJ, PINEDO HM, VEERMAN G, VERMORKEN JB, POSTMUS PE, PETERS GJ: Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice. Eur. J Cancer (1999) 35 (5):808–814.
   PubMed Web of Science ®Google Scholar
• PADRON JM, VAN MOORSEL CJ, BERGMAN AM, SMITSKAMP-WILMS W, VAN DER WILT CL, PETERS GJ: Selective cell kill of the combination of gemcitabine and cisplatin in multilayered postconfluent tumor cell cultures. Anticancer Drugs (1999) 1 0 (5):445–452.
   Google Scholar
• BERGMAN AM, RUIZ VAN HAPEREN VW, VEERMAN G, KUIPER CM, PETERS GJ: Synergistic interaction between cisplatin and gemcitabine in vitro. Clin. Cancer Res. (1996) 2(3):521–530.
   PubMedGoogle Scholar
• BRAAKHUIS BJ, RUIZ VAN HAPEREN VW, WELTERS MJ, PETERS GJ: Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. Eur. J Cancer (1995) 31A(13-14):2335–2340.
   PubMed Web of Science ®Google Scholar
• PETERS GJ, BERGMAN AM, RUIZ VAN HAPEREN VW, VEERMAN G, KUIPER CM, BRAAKHUIS BJ: Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin. Oncol (1995) 22(4 Suppl. 11):72–79.
   Google Scholar
• VAN MOORSEL CJ, PINEDO HM, VEERMAN G et al.: Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br. J. Cancer (1999) 80 (7):981–990.
   PubMed Web of Science ®Google Scholar
• CARTEI G, SACCO C, SIBAU A, PELLA N, TOP A, TABARO G: Cisplatin and gemcitabine in non-small-cell lung cancer. Ann. Oncol (1999) 10 (Suppl. 5):S57–62.
   Google Scholar
• ABRATT RP, SANDLER A, CRINO L et al.: Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery. Semin. Oncol (1998) 25 (Suppl. 9):35–43.
   Google Scholar
• RICCI S, ANTONUZZO A, GALLI L et al.: Combination chemotherapy with two different schedules of gemcitabine (GEM) plus cisplatin (CDDP) in patients with stage IIIB-W NSCLC: a multicentric randomized Phase II study. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1999) 18:480a
   Google Scholar
• PARRA HJS, CAVINA R, ANTONELLI G et al.: Superiority of three-week vs. four-week schedule of cisplatin (CDDP) and gemcitabine (GEM): results of a randomized Phase II study. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (2000) 19:546a
   Google Scholar
• SANDLER AB, NEMUNAITIS J, DENHAM C et al: Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J Gun. Oncol. (2000) 18:122–130.
   Google Scholar
• CARDENAL F, LOPEZ-CABRERIZO MP, ANTON A et al: Randomized Phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Oncol. (1999) 17(0:12–18.
   Google Scholar
• CRINO L, CONTE P, DEMARINIS F et al: A randomized trial of gemcitabine cisplatin (GP) versus m itomycin, ifosfamide and cisplatin (MIC) in advanced non-small cell lung cancer (NSCLC). A multicenter Phase III study. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1998) 17:455a.
   Google Scholar
• LANGER CJ, GANDARA DR, CALVERT P, EDELMAN MJ, OZOLS RF: Gemcitabine and carboplatin in combina-tion: an update of Phase I and Phase II studies in non-small cell lung cancer. Semin. Oncol. (1999) 26(1 Suppl. 4):12–18.
   Google Scholar
• TAKIMOTO CH, KIEFFER LV, ARBUCK SG: DNA topoisomerase I inhibitors. Cancer Chemother. Response Modifiers (1997) 1 7 :80–113 .
   Google Scholar
• NITISS JL: Investigating the biological functions of DNA topoisomerases in eukaryotic cells. Biochem. Biophys. Acta (1998) 1400(1-3):63–81.
   PubMed Web of Science ®Google Scholar
• MASUDA N, KUDOH S, FUKUOKA M: Irinotecan (CPT-11): pharmacology and clinical applications. Crit. Rev. Oncol. Hematol. (1996) 24 (1):3–26.
   PubMedGoogle Scholar
• MINAGAWA Y, KIGAWA J, ISHIHARA H, ITAMOCHI H, TERAKAWA H: Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-11, for cisplatin-resistant Hela cells. Jpn. J Cancer Res. (1994) 85 (9):966–971.
   PubMedGoogle Scholar
• KUDOH S, TAKADA M, MASUDA N et al: Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camp tothecin and cisplatin against human lung tumor xenografts. Jpn. J. Cancer Res. (1993) 84 (2) 203–207.
   PubMedGoogle Scholar
• KANO Y, SUZUKI K, AKKUTSU M et al.: Effects of CPT-11 in combination with other anti-cancer agents in culture. Int. J. Cancer (1992) 50(4):604–610.
   PubMedGoogle Scholar
• MASUDA N, FUKUOKA M, TAKADA M et al: CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin. Oncol. (1992) 10(10:1775–1780.
   PubMedGoogle Scholar
• SALTZ LB, SPRIGGS D, SCHAAF LJ et al.: Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors. J. Clin. Oncol. (1998) 16 (12):3858–3865.
   PubMed Web of Science ®Google Scholar
• UEOKA H, TABATA M, KIURA K et al: Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a Phase I study. Br. J Cancer (1999) 79(5–6)984–990.
   Google Scholar
• DE JONGE MJ, SPARREBOOM A, PLANTING AS et al: Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors. J Clin. Oncol. (2000) 18(0:187–194.
   PubMedGoogle Scholar
• DE JONGE MJ, VERWEIJ J, PLANTING AS et al.: Drug-administration sequence does not change pharmacodynamics and kinetics of irinotecan and cisplatin. Clin. Cancer Res. (1999) 5 (8):2012–2017.
   PubMedGoogle Scholar
• DE JONGE MJA, CERWEIJ J, DE BRUIJN P et al.: Pharma-cokinetic, metabolic and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin. Clin. Oncol. (2000) 1 8 (1):195–203.
   Google Scholar
• MASUDA N, FUKUOKA M, FUJITA A et al.: A Phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group. Br. J. Cancer (1998) 7 8 (2):251–256.
   Google Scholar
• DE VORE R, CRAWFORD J, DIMERY I et al.: Phase II trial of irinotecan (CPT-11) plus cisplatin (CDDP) in advanced NSCLC. Proc. Ann. Meet. Am. Soc. Clin. Oncol (1997) 16:1674a.
   Google Scholar
• MORI K, MACHIDA S, YOSHIDA T, KANO Y, TOMINAGA K: A Phase II study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. Cancer Chemother. Pharmacol. (1999) 43(6):467–470.
   PubMedGoogle Scholar
• NIHO S, NAGAO K, NISHIWAKI Y et al.: Randomized multicenter Phase III trial of irinotecan (CPT-11) and cisplatin (CDDP) versus CDDP and vindesine (VDS) in patients with advanced non-small cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1999) 18:492a.
   Google Scholar
• MASUDA N, FUKUOKA M, NEGORO S etal.: Randomized trial comparing cisplatin (CDDP) and irinotecan (CPT-11) versus CDDP and vindesine (VDS) versus CPT-11 alone in advanced non-small cell lung cancer (NSCLC), a multicenter phase III study. Proc. Ann. Meet. Am. Soc. Clin. Oncol (1999) 18:459a.
   Google Scholar
• FUKUOKA M, NAGAO K, OHASHI Y et al.: Impact of irinotecan (CPT-11) and cisplatin (CDDP) on survival in previously untreated matastatic non-small cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol (2000) 19:495a
   Google Scholar
• KAKOLYRIS S, ANDROULAKIS N, AGELAKI S et al.: Salvage treatment of taxane-refractory advanced non-small-cell lung cancer (NSCLC) with a cisplatin plus irinote-can (CPT-11) combination. Proc. Ann. Meet. Am. Soc. Clin. Oncol.(2000) 19:539a.
   Google Scholar
• SHINKAI T, EGUCHI K, SASAKI Y et al.: A randomised clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced Exp. Opin. Pharmacother. (2000) 1(6) non-small cell lung cancer. Eur. J. Cancer (1991) 27 (5):571–575.
   Google Scholar
• EINHORN LH, LOEHRER PJ, WILLIAMS SD et al.: Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer. j Clin. Oncol. (1986) 4(7):1037–1043.
   PubMedGoogle Scholar
• BONOMI PD, FINKELSTEIN DM, RUCKDESCHEL JC et al: Combination chemotherapy versus single agents followed by combination chemotherapy in stage W non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Gun. Oncol (1989) 7(10:1602–1613.
   Google Scholar
• KOSMIDIS P, BEER M, MYLONAKIS N et al.: Cisplatin/vinblastine (VP) vs. cisplatin/vinblastine ifosfamide (VIP) in non-small cell lung cancer (NSCLC). A prospective randomized Phase III study. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1992) 11 :955a.
   Google Scholar
• MASUTANI M, AKUSAWA H, KODOTA A et al: A Phase III randomized trial of cisplatin plus vindesine versus cisplatin plus vindesine plus mitomycin C versus cisplatin plus vindesine plus ifosfamide for advanced non-small-cell lung cancer. Respirology (1996) 1 (1):49–54.
   PubMedGoogle Scholar
• RUCKDESCHEL JC, FINKELSTEIN DM, ETTINGER DS et al.: Arandomized trial of the four most active regimens for metastatic non-small-cell lung cancer. j Clin. Oncol. (1986) 4(0:14–22.
   PubMedGoogle Scholar
• DHINGRA HM, VALDIVIESO M, CARR DT eta].: Random-ized trial of three combinations of cisplatin with vindesine and/or VP-16-213 in the treatment of advanced non-small-cell lung cancer. J. Clin. Oncol. (1985) 3 (2) :176–183.
   Google Scholar
• CRINO L, TONATO M, DARWISH S et al: A randomized trial of three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian lung Cancer Group. Cancer Chemother. Pharmacol. (1990) 26(0:52–56.
   PubMedGoogle Scholar
• WEICK JK, CROWLEY J, NATALE RB eta].: A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group study. J Clin. Oncol. (1991) 9 (7):1157–1162.
   Google Scholar
• FUKUOKA M, MASUDA N, FURUSE K eta].: Arandomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versusmitomyein, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin. J. Clin. Oncol. (1991) 9(4):606–613.
   Google Scholar
• ZANIBONI A, MERIGGI F, RIZZI A eta].: Paclitax el, ifosfa-mide and carboplatin for the treatment of stages IIIB and IVnon-small cell lung cancer: preliminary results. Semin. Oncol. (1997) 24(4 Suppl. 12):512-70-512-72.
   Google Scholar
• ANSARI RH, MAUER A, HOFFMAN PC et al.: A University of Chicago Consorium phase 2 study for non-small cell lung (NSCLC) cancer IIIB or IV disease with carboplatin, ifosfamide (IFEX), paclitaxel and filgrastim support-8545. Proc. Annu. Meet. Am. Soc. Clin. Oncol. (1999) 18:494a
   Google Scholar
• KOSMAS C, TSAVARIS N, POLYZOS A et al: A Phase II study of paclitax el (I) -ifo s famide (I)-cisplatin (P) (TIP) chemotherapy (CMT) in patients (pts) with advanced non-small cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol (1999) 18:512a
   Google Scholar
• ZANIBONI A, DE MARINIS F, ARDIZZONI A et al.: Taxol (I), ifosfamide (I) and carboplatin (C) is an active combination for stage IIIB-W non-small-cell lung cancer (NSCLC). A multicenter validation study. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (2000) 19:528a.
   Google Scholar
• BREAU JL, PIPERNO-NEUMANN S, BOUILLET T, COULON MA, MORERE JF: Cisplatin etoposide vinorelbine in advanced non-small cell lung cancer. Proc. Annu. Meet. Am. Soc. Clin. Oncol (1997) 16:463a
   Google Scholar
• MARANGOLO M: Vinorelbine (VB) + cisplatin (DDP) + etoposide (E) in the treatment of non-small cell lung cancer (NSCLC). Eur. J. Cancer (1993) 2 9A\(Suppl. 6):S163.
   Google Scholar
• TAN EH, ANG PT, WEE J, FONG KW, LEONG SS, KHOO KS: Vinorelbine, ifosfamide and cisplatin in advanced non-small cell lung cancer. Acta Oncol. (1999) 38 (5) :619–622.
   PubMedGoogle Scholar
• REY F, ASTOUL P, MARQUESTE L, PETITE JM, BOUTIN C, VIALLAT JR: Cisplatin, ifosfamide and vinorelbine combination chemotherapy in stage III-IV non-small-cell lung cancer: a Phase II study. Am. J Clin. Oncol (1998) 21 (5):518–522.
   PubMedGoogle Scholar
• BALDINI E, TIBALDI C, CHELLA A et al.: Phase II study of vinorelbine/ifosfamide/cisplatin for the treatment of advanced non-small-cell lung cancer. Ann. Oncol. (1996) 7(7):747–749.
   PubMedGoogle Scholar
• MONTALAR J, YUSTE A, MORALES S et al.: Vinorelbine, ifosfamide and cisplatin regimen in inoperable non small cell lung cancer patients. Eur. J Cancer (1999) 35 (Suppl. 4):S264.
   Google Scholar
• RECCHIA F, DE FILIPPIS S, LOCOCO A et al.: Phase II study of navelbine (NVB), ifosfamide (IFO) and carboplatin (CBDCA) in advanced non-small cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol (1996) 15:371
   Google Scholar
• HEJNA M, KORNEK GV, RADERER M et al.: Mitomy cin C, vinorelbine, carboplatin plus granulocyte-macrophage colony-stimulating factor for treatment of advanced non-small cell lung carcinoma. Oncology (1998) 55 (6):538–542.
   PubMedGoogle Scholar
• FURUSE K, KAWAHARA M, NISHIWAKI Y et al.: Phase I-II study of vinorelbine, mitomycin and cisplatin for stage IIIB or W non-small cell lung cancer. J Clin. Oncol. (1999) 17(10):3195–3200.
   PubMedGoogle Scholar
• BONI C, BISAGNI G, SAVOLDI L et al.: Gemcitabine, ifosfamide, cisplatin (GIP) for the treatment of stage IIIB-Wnon-small cell lung cancer (NSCLC). A phase II study of the Italian Oncology Group for Clinical Research. Proc. Ann. Meet. Am. Soc. Clin. Oncol (1998) 17:478a
   Google Scholar
• MARINI G, FERRARI VD, MARPICATI P et al.: gemcitabine (GEM) in combination with ifosfamide (IFO) and cisplatin (CDDP) in advanced non-small cell lung cancer (NSCLC): a Phase II study. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1999) 18:516a
   Google Scholar
• NADAL CV, ALIGUER MN, MAYOL XF, GRAU ES, CASTILLO MG: A Phase II trial of the combination of gemcitabine, ifosfamide and cisplatin in the treatment of advanced non-small cell lung cancer. Lung Cancer (2000) 28 (2):109–115.
   PubMedGoogle Scholar
• PEROL M, GUERIN JC, THOMAS P et al: Multicenter randomized trial comparing cisplatin-mitomycin-vinorelbine versus cisplatin-mitomycin-vindesine in advanced non-small cell lung cancer. 'Groupe Francais de Pneumo-Cancerologie'. Lung Cancer (1996) 14 (1):119–134.
   PubMedGoogle Scholar
• KAWAHARA M, FURUSE K, NISHIWAKI Y et al: Random-ized study of vinorelbine (VRB) or vindesine (VDS) with cisplatin (C) and mitomycin (M) as induction chemotherapy in stage IIIB or W non-small cell lung cancer (NSCLC) - final results. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (2000) 19:489a.
   Google Scholar
• ADAMS DJ: Synergistic of navelbine-taxol combination treatment in two human breast cancer cell lines. Proc. Ann. Meet. Am. Assoc. Cancer Res. (1994) 35:327.
   Google Scholar
• KANO Y, AKUTSU M, SUZUKI K, ANDO J, TSUNODA S: Schedule-dependent interactions between vinorel-bine and paclitaxel in human carcinoma cell lines in vitro. Breast Cancer Res. Treat. (1999) 5 6 (1):79–90.
   Google Scholar
• CULINE S, ROCH I, PINGUET F, ROMIEU G, BRESSOLLE F: Combination paclitaxel and vinorelbine therapy: in vitro cytotoxic interactions and dose-escalation study in breast cancer patients previously exposed to anthracyclines. Int. J. Oncol. (1999) 14(5):999–1006.
   PubMed Web of Science ®Google Scholar
• KNICK VC, EBERWEIN DJ, MILLER CG: Vinorelbine tartrate and paclitaxel combinations: enhanced activity against in vivo P388 murine leukemia cells. J. Natl. Cancer Inst. (1995) 87(14):1072–1077.
   PubMed Web of Science ®Google Scholar
• PARIMOO D, JEFFERS S, MUGGIA FM: Severe neurotox-icity from vinorelbine-paclitaxel combinations. J. Natl. Cancer Inst. (1996) 8 8 (15):1079–1080.
   Google Scholar
• IBRAHIM N, HORTOBAGYI GN, VALERO V et al: Phase I study of vinorelbine (NVB; Navelbine) and paclitaxel (PTX) by simultaneous (sim) 3-hr infusion (inf) for untreated metastatic breast cancer (MBC). Proc. Ann. Meet. Am. Assoc. Cancer Res. (1995) 36:1443.
   Google Scholar
• IAFFAIOLI RV, TORTORIELLO GFA, ILLIANO FCA et al: Phase I study of vinorelbine and paclitaxel in small-cell lung cancer. Cancer Chemother. Pharmacol. (1997) 41 (1):86–90.
   PubMedGoogle Scholar
• CULINE S, ROCH I, PINGUET F, ROMIEU G, BRESSOLLE F: Combination paclitaxel and vinorelbine therapy: in vitro cytotoxic interactions and dose-escalation study in breast cancer patients previously exposed to anthracyclines. Int. J. Oncol (1999) 14(5):999–1006.
   PubMed Web of Science ®Google Scholar
• BUDMAN DR, WEISELBERG L, O'MARA V et al.: A Phase I study of sequential vinorelbine followed by paclitax el. Ann. Oncol. (1999) 1 0 (7) :861–863.
   Google Scholar
• GRUNBERG SM, GREENBLATT M, OSPINA 0 et al.: Phase I study of paclitaxel/vinorelbine (P/V) for advanced non-small cell lung cancer (NSCLC). Proc. Annu. Meet. Am. Soc. Clin. Oncol (1999) 18:507a
   Google Scholar
• PEREZ JE, MACHIAVELLI MR, ROMERO AO et al.: Vinorel-bine and paclitaxel for locoregional advanced or metastatic non-small cell lung cancer (NSCLC). Proc. Annu. Meet. Am. Soc. Clin. Oncol. (1999) 18:519a
   Google Scholar
• CHANG A, DEVORE R, GU C, JOHNSON D, KENG P, ASBURY R: Paclitaxel (P) and vinorelbine (V) combina-tion in advanced non-small cell lung cancer (NSCLC); in vitro and clinical studies. Proc. Ann. Meet. Am. Assoc. Cancer Res. (1996) 37:1158a.
   Google Scholar
• MASTERS GA, MAUER AM, HOFFMAN PC et al: A Phase I-II study of paclitaxel, ifosfamide and vinorelbine with filgrastim (rhG-CSF) support in advanced non-small-cell lung cancer. Ann. Oncol. (1998) 9 (6):677–680.
   PubMedGoogle Scholar
• FRIEDMAN EL, STRAUS MJ, AMBINDER JM et al: Vinor el-bine, paclitaxel and carboplatin (VPC) for adenocarci-noma of the lung. Proc. Ann. Meet. Am. Soc. an. Oncol (2000) 19:512a
   Google Scholar
• THOMPSON DS, HAINSWORTH JD, HOPKINS LG et al: Phase I study of vinorelbine, paclitaxel and carboplatin in advanced non-small cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1998) 17:503a
   Google Scholar
• GRIMALDI M, HAINSWORTH JD, BUTTS JA et al.: Paclitaxel, carboplatin and vinorelbine in the treatment of advanced non-small cell lung cancer (NSCLC): a phase II trial of the Minnie Pearl Cancer Research Network. Proc. Ann. Meet. Am. Soc. Clin. Oncol (1999) 18:507a
   Google Scholar
• THEODOSSIOU C, COOK JA, FISHER J et al.: Interaction of gemcitabine with paclitaxel and cisplatin in human tumor cell lines. Int. J. Oncol. (1998) 12(4):825–832.
   PubMedGoogle Scholar
• EINHORN LH, RAGHAVAN D, KINDLER H et al.: A Phase I study of gemcitabine plus paclitaxel combination therapy in patients with refractory solid tumors. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1998) 17:207a
   Google Scholar
• POOLE CJ, PERREN T, HOGBERG T et al.: Phase I study to investigate the optimal dose and schedule of gemcita-bine (G) and paclitaxel (P) in combination in patients with previously treated epithelial ovarian cancer. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1998) 1 7:357a
   Google Scholar
• ROTHENBERG ML, SHARMA A, WEISS GR et al.: Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors. Ann. Oncol. (1998) 9(7):733–738.
   PubMed Web of Science ®Google Scholar
• DE PAS TM, DANESI R, SESSA C et al.: Phase I study of gemcitabine (GEM) and paclitaxel (TAX) in ch em o - naive patients with advanced non-small-cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (2000) 1 9:532a.
   Google Scholar
• ROTHENBERG ML, SHARMA A, WEISS GR et al.: Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors. Ann. Oncol. (1998) 9(7):733–738. Exp. Opin. Pharmacother. (2000) 1(6)
   Google Scholar
• GIACCONE G, SMITE, LAAN D et al: Phase VII study of paclitaxel and gemcitabine in advanced non-small cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1998) 17:486a
   Google Scholar
• ANDROULAKIS N, KOUROUSSIS C, KAKOLYRIS S et al: Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or do cetax el-based chemotherapy: a multicenter Phase II study. Ann. Oncol. (1998) 9(10):1127–1130.
   PubMed Web of Science ®Google Scholar
• KOSMIDIS PA, BACOYIANNIS N, MYLONAKIS N et al: A randomized Phase III trial of paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a preliminary analysis. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (2000) 19:488a.
   Google Scholar
• FRASCI G, PANZA N, COMELLA P et al.: Cisplatin, gemcitabine and paclitaxel in locally advanced or metastatic non-small cell lung cancer: a Phase I/11 study. J. Gun. Oncol. (1999) 1 7 (8):2316–2325.
   Google Scholar
• SO RENSEN JB, STENBYGGARD LE, HANSEN HH et al: Biweekly paclitaxel, gemcitabine and cisplatin in non-small cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1998) 17:501a
   Google Scholar
• PANZA N, FRASCI G, COMELLA P et al: Cisplatin (P)-gemcitabine (G)-paclitaxel(1) in the treatment of advanced non-small-cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol (1999) 18:492a.
   Google Scholar
• PAZ-ARES L, SANCHEZ-ROVIRA P, GOMEZ-MARTIN R et al: A Phase II study of triplet paclitaxel, cisplatin and gemcitabine (Tcg) in patients with advanced non-small-cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (2000) 1 9:546a.
   Google Scholar
• COMELLA G, COMELLA P, FRASCI G et al: Cisplatin-gemcitabine vs. cisplatin-gemcitabine-vinorelbine, vs. cisplatin-gemcitabine-paclitaxel in advanced non-small-cell lung cancer. First-stage analysis of a Southern Italy Cooperative Oncology Group (SICOG) Phase III trial. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (2000) 19:494a.
   Google Scholar
• KANO Y, AKUSTU M, TSUNODA S, MORI K, SUZUKI K, ADACHI KI: In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines. Cancer Chemother. Pharmacol. (1998) 42 (2):91–98.
   PubMedGoogle Scholar
• PEI XH, NAKANISHI Y, TAKAYAMA K et al: Effect of CPT-11 in combination with other anticancer agents in lung cancer cells. Anticancer Drugs (1997) 8(3):231–237.
   PubMed Web of Science ®Google Scholar
• ASAI G, YAMAMOTO N, SAKAI S et al: Paclitaxel (Taxol) affects pharmacokinetics of irinotecan and its metabo-lites. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (2000) 19:199a.
   Google Scholar
• MILLER LL, SOCINSKI MA, SANDLER AB et al.: Phase VII trial of paclitaxel (P), carboplatin (C) and irinotecan (CPT-11)in advanced or metastatic non-small cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1999) 18:475a.
   Google Scholar
• AOE K, KIURA K, UEOKA H etal: Effect of docetaxel with cisplatin or vinorelbine on lung cancer cell lines. Anticancer Res. (1999) 1 9 (1A):291–299.
   Google Scholar
• HINO M, KOBAYASHI K, HAYASHIHARA K et al.: In vitro combination effect of docetaxcel (RP56976) with vinca alkaloids on cancer cell line. Proc. Ann. Meet. Am. Assoc. Cancer Res. (1995) 36:1780a.
   Google Scholar
• MILLER VA, GRANT SC, NG K et al: Phase I trial of docetax el (DTX) and vinorelbine (VNR) with filgrastim in patients with advanced non-small cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1998) 17:471a.
   Google Scholar
• MILLER VA, KRUG LM, NG KK et al.: Phase II trial of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer. J. Clin. Oncol. (2000) 18 (6):1346–1350.
   PubMed Web of Science ®Google Scholar
• BALANA C, BARNADAS A, MARTIN C et al: A Phase II trial of sequence-dependent docetax el (D)/vinorelbine (V) DNA damage-induced apoptosis in patients with non-small cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol (1999) 18:463a.
   Google Scholar
• JOHNSTON E, CRAWFORD J, GARST J et al.: Phase I trial of weekly docetaxel (D) and vinorelbine (V) in advanced non-small cell lung cancer (NSCLC). Proc. Annu. Meet. Am. Soc. Clin. Oncol. (1999) 18:476a.
   Google Scholar
• HOTTON KM, KIM KM, LARSON ML et al: Phase I/II trial of docetaxel and vinorelbine in patients with non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy. Proc. Ann. Meet. Am. Soc. Clin. Oncol (1999) 18:509a.
   Google Scholar
• KOUROUSIS C, ANDROULAKIS N, KAKOLYRIS S et al.: First-line treatment of advanced non-small cell lung carcinoma with docetaxel and vinorelbine. Cancer (1998) 83 (10):2083–2090.
   PubMed Web of Science ®Google Scholar
• O'ROURKE M, GARFIELD D, ELLIS P: Phase II trial of Taxotere (1) and Navelbine (N) as first-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol (1999) 18:519a.
   Google Scholar
• GEORGOULIAS V, ANDROULAKIS N, BOUROS D et al.: Combination chemotherapy with docetaxel, vinorel-bine and cisplatin as first-line treatment of advanced non-small-cell lung cancer: a multicenter Phase II study of the Greek Cooperative Group for Lung Cancer. Lung Cancer (1998) 21 (3):213–220.
   PubMedGoogle Scholar
• ZOLI W, RICOTTI L, DAL SUSINO M et al.: Docetax el and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer. Br. J Cancer (1999) 81 (0609–615.
   Google Scholar
• SCHLO SSER NJJ, RICHELDJ, VAN ZANDWIJK N et al.: Phase I study of docetaxel and gemcitabine combina-tion chemotherapy in chemotherapy naive patients with advanced or metastatic non-small cell lung cancer. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1998) 17:499a.
   Google Scholar
• BILDAT S, HARSTRICK A, GATZEMEIER U et al.: Phase I study of docetaxel in combination with gemcitabine as first line chemotherapy in patients with metastatic Exp. Opin. Pharmacother. (2000) 1(6) non-small cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1999) 18:497a.
   Google Scholar
• LAW L, LARA PN JR, REDDY GP et al: Salvage gemcita-bine (GEM) in platinum-treated non-small-cell lung cancer (NSCLC): a Phase II California Cancer Consor-tium trial. Proc. Ann. Meet. Am. Soc. Clin. Oncol (2000) 19:533a.
   Google Scholar
• GARLAND LL, WAGNER H, SHAW GS JR et al.: Phase I study of constant dose rate infusion gemcitabine with Tax otere in advanced non-small cell lung cancer. Proc. Ann. Meet. Am. Soc. Clin. Oncol (1999) 1 8:504a.
   Google Scholar
• SPIRIDONIDIS CH, LAUFMAN LR, JONES VA, WALLANCE K, NICOL S: Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies. J. Clin. Oncol. (1998) 16(12):3866–3873.
   PubMedGoogle Scholar
• RIGAS JR, ROTHENBERG ML, DAVIS TH et al: Phase I clinical and pharmacokinetic study of docetaxel in combination with two gemcitabine infusion schedule. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1999) 18:226a.
   Google Scholar
• DUNSFORD ML, MEAD GM, BATEMAN AC, COOK T, TUNG K: Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. Ann. Oncol. (1999) 1 0 (8):943–947.
   Google Scholar
• RIZVI NA, SPIRIDONIDIS CH, DAVIS TH et al.: Docetaxel and gemcitabine combinations in non-small cell lung cancer. Semin. Oncol (1999) 2 6 (5 Suppl. 16):27–31.
   Google Scholar
• REBATTU P, QUANTIN X, MORERE J et al: A Phase II study of docetaxel (D) and gemcitabine (G) combina-tion in patients (Pts) with non-small-cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol (2000) 19:539a.
   Google Scholar
• PECTASIDES D, ASPROPOTAMITIS A, HALIKIA A et al: Combination chemotherapy with carboplatin, docetaxel and gemcitabine in advanced non-small-cell lung cancer: a Phase II study. J Clin. Oncol (1999) 17 (12) :3816–3821.
   PubMedGoogle Scholar
• BISSERY MC, VRIGNAUD P, LAVELLE F: In vivo evalua-tion of the docetaxel-irinotecan combination. Proc. Ann. Meet. Am. Assoc. Cancer Res. (1996) 37:2578a.
   Google Scholar
• BISSERY MC, COUTEAU C, OULID-AISSA D, ARMAND JP: Docetax el in combination with irinotecan: prediction of clinical maximum tolerated dose. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1997) 16:773a.
   Google Scholar
• TAKEDA K, NEGORO S, MASUDA N etal.: Phase I study of docetaxel (Doc) and irinotecan (CPT-11) for previously untreated advanced non-small cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1999) 18:524a.
   Google Scholar
• COUTEAU C, LOKIEC F, VERNILLET L et al: Phase I dose-finding and pharmacokinetic (PK) study of docetaxel (D) in combination with irinotecan (I) in advanced solid tumors. Proc. Ann. Meet. Am. Soc. an. Oncol. (1997) 16:709a.
   Google Scholar
• RICH RS, ARGIRIS A, PECCERILLO K et al.: Phase I dose escalation trial of weekly docetaxel (D) plus irinotecan (I) in patients with advanced solid tumors. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1999) 18:225a.
   Google Scholar
• ADJEI AA, GOLDBERG RM, RUBIN J et af: APhase I study of sequential irinotecan (IRN) and docetaxel (DOC) in patients with advanced solid tumors. Proc. Ann. Meet. Am. Assoc. Cancer Res. (1999) 43:603.
   Google Scholar
• SENEVIRATNE L, GARCIA AA, ROGERS M et al: Phase I clinical and pharmacokinetic (PK) trial of docetaxel (D) and irinotecan (I) administered on a weekly schedule. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (2000) 19:225a
   Google Scholar
• ESTEBAN E, LLANO JLG, VIEITEZ JM et al.: Phase I/II study of gemcitabine plus vinorelbine in non-small-cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. an. Oncol. (1998) 17:482a.
   Google Scholar
• GRIDELLI C, FRONTINI L, GULISANO M et al: Optimal doses of gemcitabine + vinorelbine (Gemvin) in the treatment of advanced non-small-cell lung cancer. A (*keep-the winner© Phase 2 study. Proc. Ann. Meet. Am. Soc. Clin. Oncol (1999) 18:477a.
   Google Scholar
• LORUSSO V, CARPAGNANO F, FRASCI G et al: Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer. J Oncol. (2000) 1 8 (2) :405–411.
   Google Scholar
• KRAJNIK G, WEIN W, GREIL R et al.: Vinorel-bine/gemcitabine in advanced non-small cell lung cancer (NSCLC): a Phase I trial. Eur. J Cancer (1998) 34 (12) :1977–1980.
   PubMedGoogle Scholar
• STEPHENSON J JR, AYLESWORTH C, JOHNSON T et al.: A Phase I study of gemcitabine plus vinorelbine on an every other week schedule. Proc. Ann. Meet. Am. Soc. Oncol. (1998) 17:253a
   Google Scholar
• HERBST R, DANG N, LYNCH C et al.: Phase I study of combination weekly gemcitabine and vinorelbine in patients with lung cancer. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1998) 17:488a
   Google Scholar
• HARBST RS, KHURI FR, JUNG M et al.: Phase II study of combination weekly gemcitabine and vinorelbine in patients with untreated or previously treated non-small-cell lung cancer. Proc. Ann. Meet. Am. Soc. Oncol. (1999) 18:462a.
   Google Scholar
• CHEN YM, WHANG-PENG J, PERNG RP et al.: A multi-center Phase II study of gemcitabine (GEM) and vinorelbine (VNR) in patients with advanced stage IIIB-IV non-small-cell lung cancer. Proc. Ann. Meet. Am. Soc. Clin. Oncol (1999) 18:481a.
   Google Scholar
• PIRKER R, KRAJNIK G, MOHN-STAUDNER A et al.: Vinorelbine/gemcitabine in advanced non-small-cell lung cancer (NSCLC): Final results of an AASLC trial. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (2000) 19:529a.
   Google Scholar
• HIRSH V, AYOUB J, CORMIER Y et al.: Completed Phase II multicenter trial with gemcitabine and vinorelbine in patients with advanced (stage IIIB & IV) non-small-cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (2000) 19:509a.
   Google Scholar
• FELIU J, LOPEZ GOMEZ L, MADRONAL C et al.: Gem cita-bineplus vinorelbine in non-small cell lung Exp. Opin. Pharmacother. (2000) 1(6) carcinoma patients age 70 years or older or patients who cannot receive cisplatin. Oncopaz Cooperative Group. Cancer (1999) 86(8):1463–1469.
   Google Scholar
• FRASCI G, LORUSSO V, PANZA N et al: Gemcitabine + vinorelbine (GV) yields better survival than vinorel-bine (V) alone in elderly non-small cell lung cancer (NSCLC) patients. Final analysis of a Southern Italy Cooperative Oncology Group (SICOG) Phase III trial. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (2000) 1 9:485a.
   Google Scholar
• BARON MG, GARCIA MJ, CHACON JI et al: A Phase II study of gemcitabine, cisplatin and vinorelbine in patients with advanced non-small cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol (1998) 17:469a.
   Google Scholar
• DORTA J, MARTIN G, CONSTENLA M et al.: A Phase II study of gemcitabine, cisplatin and vinorelbine in patients with advanced non-small cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol (1998) 17:482a.
   Google Scholar
• GINOPOULOS P, MASTRONIKOLIS NS, GIANNIOS J et al: A Phase II study with vinorelbine, gemcitabine and cisplatin in the treatment of patients with stage IIIb-W non-small cell lung cancer (NSCLC). Lung Cancer (1999) 23 (1):31–37.
   PubMedGoogle Scholar
• FRASCI G, PANZA N, COMELLA P et al.: Cisplatin, gemcitabine and vinorelbine in locally advanced or metastatic non-small-cell lung cancer: a Phase I study. Ann. Oncol. (1997) 8(10):1045–1048.
   PubMedGoogle Scholar
• COMELLA P, FRASCI G, PANZA N et al.: Randomized trial comparing cisplatin, gemcitabine and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J Clin. Oncol. (2000) 18 (7):1451–1457.
   PubMedGoogle Scholar
• MOGI H, HASEGAWA Y, WATANABE A, NOMURA F, SAKA H, SHIMOKATA K: Combination effects of cisplatin, vinorelbine and irinotecan in non-small-cell lung cancer cell lines in vitro. Cancer Chem other. Pharmacol. (1997) 39 (3) :199–204.
   PubMedGoogle Scholar
• BAHADORI HR, OGRETMEN B, ROCHA LIMA CM et al: Evaluation of irinotecan (CPT-11) and gemcitabine (G) as single agents and in combination in small-cell lung cancer cells. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1998) 17:477a
   Google Scholar
• ANONYMOUS: Dexamethasone and CPT-11 induce apoptosis in myeloma cells by downreg-ulation of bc1-2 whereas Taxol, melphalan and gemcitabine induce apoptosis by phosphorylation of bc1-2. Proc. Ann. Meet. Am. Assoc. Cancer Res. (1997) 38:3560a.
   Google Scholar
• KANZAWA F, SAIJO N: In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model. Semin. Oncol (1997) 24 (Suppl. 7) : S7-8-S7–16.
   Google Scholar
• ROCHA LIMA CM, ECKARDT JR, LEONG SS et al.: Single-agent gemcitabine and gemcitabine/irinotecan combination (irimogem) in non-small cell lung cancer. Semin. Oncol (1999) 2 6 (5 Suppl. 16):43–50.
   Google Scholar
• HUSSEIN A, BIRCH R, WALLER J et al: Preliminary results of a randomized study comparing paclitaxel and carboplatin (PC) with or without gemcitabine (G) in newly diagnosed non small cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (2000) 19:504a.
   Google Scholar
• KELLY K, CROWLEY J, BUNN PA, LIVINGSTONE RB, GANDARA DR: A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC). A Southwest Oncology Group (SWOG) Trial. Proc. Am. Soc. Clin. Oncol. (1999) 18:461a.
   Google Scholar
• ROSZKOWSKI K: Taxotere® (1XT) versus best suppor-tive care (BSC) in chemonaive patients with unresectable non-small cell lung cancer (NSCLC): final results of the Phase III study. Eur. J Cancer (1999) 35 (Suppl. 4):S246.
   Google Scholar
• COMELLA P, FRASCI G, DE CATALDIS G et al.: Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano. Br. J. Cancer (1996) 74(11):1805–1811.
   Google Scholar
• COLUCCI G, GEBBIA V, GALETTA D, RICCARDI F, CARIELLO S, GEBBIA N: Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs. the opposite sequence in advanced unresectable stage III and metastatic stage IV non-small-cell lung cancer: a prospective randomized study of the Southern Italy Oncology Group (GOIM). Br. J. Cancer (1994) 76(10:1509–1517.
   Google Scholar
• VANSTEENKISTE J, VANDEBROEK J, NACKAERTS K et al: Symptom control in advanced non-small-cell lung cancer (NSCLC): a multicenter prospective random-ized Phase III study of single agent gemcitabine (GEM) versus cisplatin-vindesine (PV). Proc. Ann. Meet. Am. Soc. Clin. Oncol (2000) 19:488a.
   Google Scholar
• LOKICH J, ANDERSON N, BERN M et al.: Paclitaxel, cisplatin, etoposide combination chemotherapy: a multifractionated bolus dose schedule for non-small cell lung cancer. Eur. J Cancer (1998) 34 (5):659–663.
   PubMedGoogle Scholar
• CROWN JP, DONNELLAN P, O'SULLIVAN C etal.: Phase TM evaluation of escalating dose docetaxel (Taxotere,1), ifosfamide (I) and cisplatin (C) with lenograstim (L) support, in patients with stage III/IV non small cell lung cancer (NSCLCa): an Irish Clinical Oncology Research Group (ICORG) study. Proc. Annu. Meet. Am. Soc. Clin. Oncol (1999) 18:477a
   Google Scholar
• FUJITA A, TAKABATAKE H, TAGAKI S, SEKINE K: Phase I study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in advanced non-small cell lung cancer. Oncology (1999) 5 6 (4):301–307.
   Google Scholar
• MONNIER A, DOUILLARD JY, LEROUGE D et al: Results of a Phase II study with Taxol (paclitaxel) and Gemzar (gemcitabine) in metastatic n on -sm all-cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (2000) 19:516a.
   Google Scholar
• BHATIA S, NG E, ANSARI R et al.: A Phase II study of paclitaxel (P) and gemcitabine (G) in patients with advanced non-small-cell lung cancer - A Hoosier Exp. Opin. Pharmacother. (2000) 1(6) Oncology Group Study. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (2000) 19:532a.
   Google Scholar
• EDELMAN, G, MELVILLE S, MEYER W, NAPIER S: A multicenter, Phase II study of combination paclitaxel/gemcitabine in previously untreated, non-resectable, stage IIITIVnon-small-cell lung cancer (NSCLC) cancer patients (Pts). Proc. Annu. Meet. Am. Soc. Clin. Oncol. (2000) 19:536a.
   Google Scholar
• HAINSWORTH JD, BURRIS HA, ERLAND JB et al: Phase VII trial of paclitaxel by 1-hour infusion, carboplatin and gemcitabine in the treatment of patients with advanced non-small cell lung carcinoma. Cancer (1999) 85(6):1269–1276.
   PubMedGoogle Scholar
• KELLY K, PRINDIVILLE S, BUNN PA et al.: A Phase I study of paclitax el (P), carboplatin (C) and gemcitabine (G) in advanced non-small-cell lung cancer (NSCLC): a university of Colorado Cancer Center study. Proc. Ann. Meet. Am. Soc. Clin. Oncol (1998) 17:490a
   Google Scholar
• FAVARETTO A, PACCAGNELLA A, ONIGA F et al.: Paclitaxel and carboplatin in combination with gemcitabine (PCG); a Phase I-II trial in non-small-cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (2000) 19:512a.
   Google Scholar
• GEORGOULIAS V, KOUROUSIS C, ANDROULAKIS N et al.: Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter Phase II trial. J. Gun. Oncol. (1999) 17(3):914–920.
   Google Scholar
• SPIRIDONIDIS CH, LAUFMAN LR, CARMAN L et al: Second-line chemotherapy with weekly gemcitabine (GEM) and monthly docetax el (DOC) in patients (Pts) with non-small-cell lung cancer (NSCLC): a Phase II study. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (2000) 19:503a.
   Google Scholar
• BARR F, MISKY H, CLINTHORNE D et al.: APhase III study of gemcitabine and vinorelbine salvage chemotherapy for taxane resistant non-small-cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol (1999) 18:496a.
   Google Scholar
• HAINS WORTH JD, BURRIS HA, LITCHY S et al: Gem cita-bineand vinorelbine in the second-line treatment of non-small cell lung carcinoma patients. Cancer (2000) 88 (6):1353–1358.
   PubMedGoogle Scholar
• LAACK E, MENDE T, SAAL JG et al.: Amulticenter Phase II trial with gemcitabine (GEM) and vinorelbine (VNR) in the treatment of non-small-cell lung cancer (NSCLC) stage IIIB and W. Eur. J. Cancer (1999) 35 (Suppl. 4):S252.
   Google Scholar
• CHANG A, BOROS L, ASBURY R et al: Effective salvage treatment for metastatic non-small-cell lung cancer (NSCLC): Combination of gemcitabine, vinorelbine and cisplatin (GVC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (2000) 19:514a.
   Google Scholar
• GRALLA RJ, RITTENBERG CN, SILVERMAN CR et al: gemcitabine (G) +vinorelbine (V) in combination with m ito my cin (M) in non-small-cell lung cancer (NSCLC): results of a Phase land II study of an active outpatient regimen. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1998) 17:486a.
   Google Scholar
• RECCHIA F, DE FILIPPIS S, SAGGIO G etal.: Phase II study of gemcitabine, ifosfamide and vinorelbine in advanced non-small-cell lung cancer. Activity and toxicity of a platinum-free regimen. Proc. Ann. Meet. Am. Soc. Clin. Oncol (1999) 18:489a.
   Google Scholar
• CASTELLANO D, LIANES P, CALZAS J et al.: Non-cisplatin-based chemotherapy for advanced non-small-cell lung cancer (NSCLC): a Phase II study with gemcitabine (G), ifosfamide (I) and vinorelbine (N). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1998) 17 :480a.
   Google Scholar
• COMELLA P, FRASCI G, PANZA N et al: Cisplatin, gemcitabine and vinorelbine combination therapy in advanced non-small-cell lung cancer: a Phase II randomized study of the Southern Italy Cooperative Oncology Group. J. Clin. Oncol. (1999) 17(5):1526–1534. Ikuo Sekinet & Nagahiro Saijo
   Google Scholar